 |
Vol.60 No.7 contents | Japanese/English |
 | Full Text of PDF (276K) Article in Japanese |
- Case Report -
Acute Demyelinating Polyneuropathy Occurring Four Days After Nivolumab Administration in a Patient with Lung Adenocarcinoma
Yumi Ohira1, Zen Kobayashi1, Takaaki Yamashita1, Shoichiro Ishihara1, Hiroyuki Tomimitsu1, Shuzo Shintani11Department of Internal Medicine, JA Toride Medical Center, Japan
Background. Immune checkpoint inhibitors (ICIs) have been used for patients with several cancers, including non-small cell lung cancer, and sometimes result in various immune-related adverse events (irAEs), such as peripheral neuropathy. The time to the onset of peripheral neuropathy post-ICI administration ranges between five days and five months. We herein report a patient with advanced lung adenocarcinoma who developed acute demyelinating polyneuropathy four days after the administration of nivolumab. Case. A 77-year-old man with advanced lung adenocarcinoma presented with symmetric and lower limb-predominant motor and sensory disturbance 4 days after nivolumab administration and became unable to walk. Nerve conduction studies resulted in a diagnosis of demyelinating polyneuropathy. The motor and sensory disturbance ameliorated with intravenous immunoglobulin plus methylprednisolone pulse therapy. Conclusions. On comparison with previous reports of peripheral neuropathy post-ICI administration, the time to the onset of peripheral neuropathy in our patient was the shortest. Clinicians should be aware of acute demyelinating polyneuropathy as an irAE that can occur within one week after nivolumab administration.
key words: Acute demyelinating polyneuropathy, Immune-related adverse events, Nivolumab, Non-small cell lung cancer
Received: May 27, 2020
Accepted: August 20, 2020
JJLC 60 (7): 991-994, 2020
